Aurinia to Participate in Jefferies London Healthcare Conference

11/14/24 6:00:00 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $AUPH alert in real time by email

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company) today announced that the Company's management team will attend the Jefferies Healthcare Conference in London, November 19-21, 2024.

Aurinia management will host one-on-one meetings with investors and will participate in a fireside chat and Q&A session on Wednesday, November 20, at 12:00 PM GMT/7:00 AM EST. This session will not include a webcast.

About Aurinia

Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS^®(voclosporin), the first FDA-approved oral therapy dedicated to the treatment of adult patients with active lupus nephritis. Aurinia is also developing AUR200, a differentiated, potential best-in-class therapy for autoimmune diseases that targets both BAFF (B-cell Activating Factor) and APRIL (A Proliferation-Inducing Ligand).

View source version on businesswire.com: https://www.businesswire.com/news/home/20241114401812/en/

Get the next $AUPH alert in real time by email

Date	Price Target	Rating	Analyst
11/4/2022		Outperform → Perform	Oppenheimer
5/5/2022	$34.00 → $25.00	Overweight	Cantor Fitzgerald
3/8/2022	$30.00 → $22.00	Outperform	SVB Leerink
3/1/2022	$31.00 → $27.00	Outperform	RBC Capital
2/23/2022	$34.00 → $31.00	Outperform	RBC Capital
12/10/2021	$33.00 → $31.00	Perform → Outperform	Oppenheimer
11/4/2021	$32.00 → $33.00	Perform	Oppenheimer
11/4/2021	$35.00 → $40.00	Buy	HC Wainwright & Co.

Aurinia to Participate in Jefferies London Healthcare Conference

Chat with this insight

Recent Analyst Ratings for $AUPH

$AUPH Financials

Live finance-specific insights

Aurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended December 31, 2024 and Provides Update on Recent Corporate Progress

Aurinia Pharmaceuticals to Release 2024 Fourth Quarter and Full Year Financial and Operational Results on February 27, 2025

Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2024 Financial and Operational Results, Announces Strategic Restructuring to Sharpen Focus on Continued LUPKYNIS® Growth and AUR200 Development

$AUPH SEC Filings

SEC Form DEFA14A filed by Aurinia Pharmaceuticals Inc

SEC Form DEF 14A filed by Aurinia Pharmaceuticals Inc

Amendment: SEC Form SCHEDULE 13D/A filed by Aurinia Pharmaceuticals Inc

$AUPH Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Chief Medical Officer Keenan Greg sold $68,350 worth of shares (8,305 units at $8.23), decreasing direct ownership by 5% to 153,484 units (SEC Form 4)

Chief Executive Officer Greenleaf Peter was granted 624,433 shares and sold $2,871,124 worth of shares (360,540 units at $7.96), increasing direct ownership by 17% to 1,788,945 units (SEC Form 4)

Chief Medical Officer Keenan Greg was granted 62,583 shares and sold $97,912 worth of shares (12,239 units at $8.00), increasing direct ownership by 45% to 161,789 units (SEC Form 4)

$AUPH FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

FDA Approval for LUPKYNIS

$AUPH Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Aurinia Pharmaceuticals Inc

SEC Form SC 13D filed by Aurinia Pharmaceuticals Inc

SEC Form SC 13D/A filed by Aurinia Pharmaceuticals Inc (Amendment)

$AUPH Press Releases

Fastest customizable press release news feed in the world

ISS Recommends That Aurinia Shareholders Vote "FOR" All Proposals at 2025 Annual General Meeting

Concerned Shareholders of Aurinia Pharmaceuticals Announce Their Intention to Withhold Support for CEO Peter Greenleaf at 2025 Annual Meeting

Aurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended December 31, 2024 and Provides Update on Recent Corporate Progress

$AUPH Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

$AUPH Leadership Updates

Live Leadership Updates

Director Tang Kevin bought $12,713,126 worth of shares (1,600,000 units at $7.95) (SEC Form 4)

Director Tang Kevin bought $10,822,000 worth of shares (1,200,000 units at $9.02) (SEC Form 4)

Aurinia Pharmaceuticals Appoints Craig Johnson to Board of Directors to Support Next Phase of Growth

Aurinia Announces 2024 Annual General Meeting Results

Aurinia Board of Directors Appoints Dr. Robert T. Foster as New Board Director And Enters Cooperation Agreement with Shareholder MKT Capital

$AUPH Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Aurinia Pharma downgraded by Oppenheimer

Cantor Fitzgerald resumed coverage on Aurinia Pharma with a new price target

SVB Leerink reiterated coverage on Aurinia Pharmaceuticals with a new price target

Recent Analyst Ratings for
$AUPH

$AUPH
Financials

$AUPH
SEC Filings

$AUPH
Insider Trading

$AUPH
FDA approvals

$AUPH
Large Ownership Changes

$AUPH
Press Releases

$AUPH
Insider Purchases

$AUPH
Leadership Updates

$AUPH
Analyst Ratings